The Cisplatin Gap Closes: AstraZeneca's VOLGA Trial Rewrites the Standard of Care for Bladder Cancer

For roughly half of all patients diagnosed with muscle-invasive bladder cancer, the standard treatment conversation has always started with a problem. Cisplatin-based chemotherapy, the backbone of neoadjuvant therapy before radical cystectomy, is simply not an option for patients with impaired kidney function, hearing loss, peripheral neuropathy, or other comorbidities that make the drug too dangerous to administer. For decades, those patients faced a stark choice: undergo surgery alone, with all the recurrence risk that entails, or accept that the most effective perioperative regimens were not designed for them.

On May 14, 2026, AstraZeneca announced results from the Phase 3 VOLGA trial that begin to close that gap in a meaningful way. Perioperative treatment with Imfinzi (durvalumab) in combination with neoadjuvant enfortumab vedotin delivered statistically significant improvements in both event-free survival and overall survival compared to standard-of-care surgery in patients with muscle-invasive bladder cancer who were ineligible for or had declined cisplatin. The data represent AstraZeneca's third consecutive positive readout in bladder cancer, following the NIAGARA and POTOMAC trials, and they arrive at a moment when the perioperative immunotherapy paradigm is rapidly becoming the new standard across the disease spectrum.

What the VOLGA Data Actually Show

The VOLGA trial enrolled 695 patients across 182 centers in 25 countries, randomizing them in a 1:1:1 ratio across three arms. The comparator arm received radical cystectomy with or without approved adjuvant therapy. The two experimental arms tested perioperative durvalumab with neoadjuvant enfortumab vedotin, with one arm adding tremelimumab (Imjudo), AstraZeneca's CTLA-4 inhibitor, to the regimen.

The headline result is the doublet arm: durvalumab plus enfortumab vedotin achieved statistically significant improvements in both event-free survival and overall survival versus surgery alone. That dual endpoint achievement matters. Event-free survival is a meaningful surrogate in the perioperative setting, capturing recurrence, progression before surgery, and failure to undergo cystectomy. But overall survival is the endpoint that changes clinical practice and shapes regulatory decisions, and hitting it at an interim analysis in a curative-intent trial is a result that demands attention.

The triplet arm, adding tremelimumab to the doublet, also met the event-free survival endpoint with statistical significance and showed a favorable trend for overall survival. However, the overall survival data for the triplet did not cross the prespecified statistical boundary at this interim analysis and will be formally reassessed at a future timepoint. That nuance is worth preserving: the triplet is not a failed arm, but its OS story is incomplete. The doublet's story, by contrast, is already compelling.

Safety was consistent with the known profiles of the individual agents. No new signals emerged, which matters in a population that is, by definition, medically fragile enough to be excluded from cisplatin-based therapy.

The Population That Has Been Waiting

The clinical significance of VOLGA is inseparable from the population it was designed to serve. Approximately 50 percent of patients with muscle-invasive bladder cancer are ineligible for cisplatin, typically because of reduced kidney function, a performance status that precludes aggressive chemotherapy, or comorbidities that make the drug's toxicity profile unacceptable. These are not marginal patients. They represent roughly half of the 117,500 people treated annually for muscle-invasive disease, and they have historically been managed with surgery alone, a strategy that leaves approximately half of them experiencing disease recurrence despite undergoing a major operation that removes their bladder entirely.

The NIAGARA trial, which established perioperative durvalumab plus cisplatin-based chemotherapy as a new standard of care in 2025, was a landmark result. But it was a landmark for the cisplatin-eligible half of the population. VOLGA is the answer for the other half, and the fact that it delivers an overall survival benefit, not just a surrogate endpoint improvement, gives it a different kind of clinical weight.

The Competitive Landscape and What It Means

VOLGA does not exist in isolation. The KEYNOTE-905 trial, evaluating perioperative enfortumab vedotin plus pembrolizumab in the same cisplatin-ineligible population, also demonstrated significant event-free survival and overall survival improvements. That trial's data were published in the New England Journal of Medicine and have already prompted an FDA priority review for the combination. The bladder cancer field is now in the unusual position of having two perioperative regimens with overall survival data in cisplatin-ineligible patients, both built around enfortumab vedotin paired with a checkpoint inhibitor.

The practical question for oncologists and urologists will be how to choose between durvalumab and pembrolizumab as the immunotherapy partner. Head-to-head trials in this setting are unlikely to happen. Clinicians will rely on cross-trial comparisons, institutional experience, dosing schedules, and payer dynamics to guide prescribing decisions. That is an imperfect framework, but it is the reality of a field moving faster than randomized comparative evidence can follow.

What the convergence of VOLGA and KEYNOTE-905 does establish, unambiguously, is that the era of surgery alone for cisplatin-ineligible muscle-invasive bladder cancer is ending. Two independent Phase 3 trials, with different checkpoint inhibitors but the same antibody-drug conjugate backbone, have now demonstrated that perioperative immunotherapy plus enfortumab vedotin extends survival in this population. That level of convergent evidence is rare in oncology, and it will be difficult for any guideline committee or regulatory agency to ignore.

What Comes Next

AstraZeneca has indicated it will present the full VOLGA dataset at an upcoming medical meeting and share the data with global regulatory authorities. The timing is significant: the American Urological Association annual meeting is underway this week, and the European Society for Medical Oncology congress later in the year would be a natural venue for a full data presentation. Regulatory submissions in the United States, European Union, and other major markets are the logical next step, and the overall survival data from the doublet arm give those submissions a strong foundation.

For the roughly 60,000 Americans diagnosed annually with muscle-invasive bladder cancer who cannot receive cisplatin, the VOLGA results represent something concrete: a perioperative regimen with proven survival benefit, a manageable safety profile, and a regulatory pathway that is now clearly in motion. The cisplatin gap in bladder cancer treatment has been a quiet inequity for decades, shaping outcomes for patients who were simply unlucky enough to have kidneys that could not tolerate the standard drug. The data emerging from VOLGA and KEYNOTE-905 suggest that gap is finally, measurably closing.